Compare NXP Semiconductors N.V. Common Stock (NXPI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NXP Semiconductors N.V. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? NXP Semiconductors N.V. Common Stock trades at $220 (market cap $57.07B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 7.6× Spyre Therapeutics Inc. Common Stock's market cap, and NXP Semiconductors N.V. Common Stock pays a 1.79% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NXP Semiconductors N.V. Common Stock for 5 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NXPI | SYRE | |
|---|---|---|
Market Cap | $57.07B | $7.52B |
Volume | 3,033,835 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $332.67 | $108.92 |
52-Week Low | $184.19 | $22.18 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $65.18B | $6.52B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.
NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NXP Semiconductors N.V. Common Stock
NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
